For the quarter ended September 2026, West Pharmaceutical Services (WST Quick QuoteWST - Free Report) reported revenue of $874.5 million, up 8.7% over the same period last year. EPS came in at $2.66, compared to $1.96 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $825.93 million, representing a surprise of +5.88%. The company delivered an EPS surprise of +22.02%, with the consensus EPS estimate being $2.18.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how West Pharmaceutical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Sales- West Vantage: $145.7 million versus the two-analyst average estimate of $144.68 million. The reported number represents a year-over-year change of -7.3%.
• Net Sales- Proprietary Products: $728.8 million compared to the $682.68 million average estimate based on two analysts. The reported number represents a change of +12.6% year over year.
• Gross Profit- Proprietary Products: $323.4 million compared to the $297.25 million average estimate based on two analysts.
• Gross Profit- West Vantage: $24 million compared to the $23.8 million average estimate based on two analysts.

View all Key Company Metrics for West Pharmaceutical here>>>

Shares of West Pharmaceutical have returned +8.9% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.